BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Spengler EK, Loomba R. Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Mayo Clin Proc 2015;90:1233-46. [PMID: 26219858 DOI: 10.1016/j.mayocp.2015.06.013] [Cited by in Crossref: 127] [Cited by in F6Publishing: 112] [Article Influence: 21.2] [Reference Citation Analysis]
Number Citing Articles
1 Hendy OM, Rabie H, El Fouly A, Abdel-Samiee M, Abdelmotelb N, Elshormilisy AA, Allam M, Ali ST, Bahaa El-Deen NM, Abdelsattar S, Mohamed SM. The Circulating Micro-RNAs (-122, -34a and -99a) as Predictive Biomarkers for Non-Alcoholic Fatty Liver Diseases. Diabetes Metab Syndr Obes 2019;12:2715-23. [PMID: 31908512 DOI: 10.2147/DMSO.S231321] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
2 George ES, Roberts SK, Nicoll AJ, Reddy A, Paris T, Itsiopoulos C, Tierney AC. Non-alcoholic fatty liver disease patients attending two metropolitan hospitals in Melbourne, Australia: high risk status and low prevalence. Intern Med J 2018;48:1369-76. [PMID: 29845719 DOI: 10.1111/imj.13973] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Colgan TJ, Van Pay AJ, Sharma SD, Mao L, Reeder SB. Diurnal Variation of Proton Density Fat Fraction in the Liver Using Quantitative Chemical Shift Encoded MRI. J Magn Reson Imaging 2020;51:407-14. [PMID: 31168893 DOI: 10.1002/jmri.26814] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Casler K, Trees K, Bosak K. Providing Care for Fatty Liver Disease Patients: Primary Care Nurse Practitioners' Knowledge, Actions, and Preparedness. Gastroenterol Nurs 2020;43:E184-9. [PMID: 32889968 DOI: 10.1097/SGA.0000000000000487] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Xiao J, Wang F, Liong EC, So K, Tipoe GL. Lycium barbarum polysaccharides improve hepatic injury through NFkappa-B and NLRP3/6 pathways in a methionine choline deficient diet steatohepatitis mouse model. International Journal of Biological Macromolecules 2018;120:1480-9. [DOI: 10.1016/j.ijbiomac.2018.09.151] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
6 Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice. J Hepatol. 2016;65:1006-1016. [PMID: 27312947 DOI: 10.1016/j.jhep.2016.06.005] [Cited by in Crossref: 176] [Cited by in F6Publishing: 159] [Article Influence: 35.2] [Reference Citation Analysis]
7 Pilling D, Karhadkar TR, Gomer RH. High-Fat Diet-Induced Adipose Tissue and Liver Inflammation and Steatosis in Mice Are Reduced by Inhibiting Sialidases. Am J Pathol 2021;191:131-43. [PMID: 33039353 DOI: 10.1016/j.ajpath.2020.09.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
8 Qiu Y, Wang S, Wan T, Ye M, Jiang R, Pei L, Yang L. Blood-based novel biomarkers for nonalcoholic steatohepatitis. Biomark Med 2018;12:501-15. [PMID: 29712439 DOI: 10.2217/bmm-2017-0361] [Reference Citation Analysis]
9 Sanai FM, Abaalkhail F, Hasan F, Farooqi MH, Nahdi NA, Younossi ZM. Management of nonalcoholic fatty liver disease in the Middle East. World J Gastroenterol 2020; 26(25): 3528-3541 [PMID: 32742124 DOI: 10.3748/wjg.v26.i25.3528] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Kim Y, Natarajan SK, Chung S. Gamma-Tocotrienol Attenuates the Hepatic Inflammation and Fibrosis by Suppressing Endoplasmic Reticulum Stress in Mice. Mol Nutr Food Res 2018;62:1800519. [DOI: 10.1002/mnfr.201800519] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
11 Herath HMM, Kodikara I, Weerarathna TP, Liyanage G. Prevalence and associations of non-alcoholic fatty liver disease (NAFLD) in Sri Lankan patients with type 2 diabetes: A single center study. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2019;13:246-50. [DOI: 10.1016/j.dsx.2018.09.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
12 Arista Romeu EJ, Escobedo G, Campos-espinosa A, Romero-bello II, Moreno-gonzález J, Fabila-bustos DA, Reed AV, Isakina SS, Vázquez JMDLR, Guzmán C. Diffuse reflectance spectroscopy accurately discriminates early and advanced grades of fatty liver in mice. J Biomed Opt 2018;23:1. [DOI: 10.1117/1.jbo.23.11.115005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
13 Görtz RS, Schellhaas B. Sonographie bei Leberzirrhose: von der TIPSS-Funktionsprüfung zur LI-RADS®-Klassifikation. Gastroenterologe 2018;13:292-7. [DOI: 10.1007/s11377-018-0270-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
14 Puthenpura MM, Patel V, Fam J, Katz L, Tichansky DS, Myers S. The Use of Transient Elastography Technology in the Bariatric Patient: a Review of the Literature. Obes Surg 2020;30:5108-16. [PMID: 32981002 DOI: 10.1007/s11695-020-05002-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Ejima C, Kuroda H, Ishizaki S. A novel diet-induced murine model of steatohepatitis with fibrosis for screening and evaluation of drug candidates for nonalcoholic steatohepatitis. Physiol Rep 2016;4:e13016. [PMID: 27821715 DOI: 10.14814/phy2.13016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
16 Noureddin M, Zhang A, Loomba R. Promising therapies for treatment of nonalcoholic steatohepatitis. Expert Opin Emerg Drugs 2016;21:343-57. [PMID: 27501374 DOI: 10.1080/14728214.2016.1220533] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
17 Paka L, Smith DE, Jung D, McCormack S, Zhou P, Duan B, Li JS, Shi J, Hao YJ, Jiang K, Yamin M, Goldberg ID, Narayan P. Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease. World J Gastroenterol 2017; 23(23): 4181-4190 [PMID: 28694658 DOI: 10.3748/wjg.v23.i23.4181] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
18 Zhou W, Wang Y, Wu Y, Yang J, Xu L, Yang Y. Serum CTRP3 level is inversely associated with nonalcoholic fatty liver disease: A 3-y longitudinal study. Clin Chim Acta 2018;479:79-83. [PMID: 29305845 DOI: 10.1016/j.cca.2018.01.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Zhang J, Tu M, Liu Z, Zhang G. Soluble epoxide hydrolase as a therapeutic target for obesity-induced disorders: roles of gut barrier function involved. Prostaglandins Leukot Essent Fatty Acids 2020;162:102180. [PMID: 33038829 DOI: 10.1016/j.plefa.2020.102180] [Reference Citation Analysis]
20 Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES, Goudevenos J, Elisaf MS, Germanidis G, Giouleme O, Karagiannis A, Karvounis C, Katsiki N, Kotsis V, Kountouras J, Liberopoulos E, Pitsavos C, Polyzos S, Rallidis LS, Richter D, Tsapas AG, Tselepis AD, Tsioufis K, Tziomalos K, Tzotzas T, Vasiliadis TG, Vlachopoulos C, Mikhailidis DP, Mantzoros C. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism 2017;71:17-32. [DOI: 10.1016/j.metabol.2017.02.014] [Cited by in Crossref: 132] [Cited by in F6Publishing: 120] [Article Influence: 33.0] [Reference Citation Analysis]
21 Alsabaani AA, Mahfouz AA, Awadalla NJ, Musa MJ, Al Humayed SM. Non-Alcoholic Fatty Liver Disease among Type-2 Diabetes Mellitus Patients in Abha City, South Western Saudi Arabia. Int J Environ Res Public Health 2018;15:E2521. [PMID: 30423871 DOI: 10.3390/ijerph15112521] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
22 Rikhi R, Singh T, Modaresi Esfeh J. Work up of fatty liver by primary care physicians, review. Ann Med Surg (Lond) 2020;50:41-8. [PMID: 31993196 DOI: 10.1016/j.amsu.2020.01.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Wang C, Zhu C, Shao L, Ye J, Shen Y, Ren Y. Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease. Mediators Inflamm. 2019;2019:7659509. [PMID: 31341422 DOI: 10.1155/2019/7659509] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
24 Crooks DR, Maio N, Lane AN, Jarnik M, Higashi RM, Haller RG, Yang Y, Fan TW, Linehan WM, Rouault TA. Acute loss of iron-sulfur clusters results in metabolic reprogramming and generation of lipid droplets in mammalian cells. J Biol Chem 2018;293:8297-311. [PMID: 29523684 DOI: 10.1074/jbc.RA118.001885] [Cited by in Crossref: 38] [Cited by in F6Publishing: 23] [Article Influence: 12.7] [Reference Citation Analysis]
25 Minicozzi MR, von Hippel FA, Furin CG, Buck CL. Sodium perchlorate induces non-alcoholic fatty liver disease in developing stickleback. Environ Pollut 2019;251:390-9. [PMID: 31100570 DOI: 10.1016/j.envpol.2019.05.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
26 Gao C, Marcketta A, Backman JD, O'Dushlaine C, Staples J, Ferreira MAR, Lotta LA, Overton JD, Reid JG, Mirshahi T, Regeneron Genetics Center, Geisinger Regeneron Discovehr Collaboration, Baras A, Abecasis G, Shuldiner AR, Van Hout CV, McCarthy S. Genome-wide association analysis of serum alanine and aspartate aminotransferase, and the modifying effects of BMI in 388k European individuals. Genet Epidemiol 2021;45:664-81. [PMID: 34184762 DOI: 10.1002/gepi.22392] [Reference Citation Analysis]
27 Brattain LJ, Telfer BA, Dhyani M, Grajo JR, Samir AE. Objective Liver Fibrosis Estimation from Shear Wave Elastography.Annu Int Conf IEEE Eng Med Biol Soc. 2018;2018:1-5. [PMID: 30440285 DOI: 10.1109/EMBC.2018.8513011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
28 Hülsmeier AJ, Tobler M, Burda P, Hennet T. Glycosylation site occupancy in health, congenital disorder of glycosylation and fatty liver disease. Sci Rep 2016;6:33927. [PMID: 27725718 DOI: 10.1038/srep33927] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
29 Hung MC, Chen CF, Tsou MT, Lin HH, Hwang LC, Hsu CP. Relationship Between Gallstone Disease and Cardiometabolic Risk Factors in Elderly People with Non-Alcoholic Fatty Liver Disease. Diabetes Metab Syndr Obes 2020;13:3579-85. [PMID: 33116709 DOI: 10.2147/DMSO.S266947] [Reference Citation Analysis]
30 Tricò D, Caprio S, Rosaria Umano G, Pierpont B, Nouws J, Galderisi A, Kim G, Mata MM, Santoro N. Metabolic Features of Nonalcoholic Fatty Liver (NAFL) in Obese Adolescents: Findings From a Multiethnic Cohort. Hepatology 2018;68:1376-90. [PMID: 29665034 DOI: 10.1002/hep.30035] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 19.0] [Reference Citation Analysis]
31 Ma X, Huang Y, Ding Y, Shi L, Zhong X, Kang M, Li C. Analysis of piRNA expression spectra in a non-alcoholic fatty liver disease mouse model induced by a methionine- and choline-deficient diet. Exp Ther Med 2020;19:3829-39. [PMID: 32346447 DOI: 10.3892/etm.2020.8653] [Reference Citation Analysis]
32 Koch TR, Shope TR, Smith CI. Diet and Activity Programs Are Ineffective in Nonalcoholic Steatohepatitis. Mayo Clinic Proceedings 2016;91:683-4. [DOI: 10.1016/j.mayocp.2016.02.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
33 Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15:397-411. [PMID: 29748586 DOI: 10.1038/s41575-018-0011-z] [Cited by in Crossref: 301] [Cited by in F6Publishing: 285] [Article Influence: 150.5] [Reference Citation Analysis]
34 Collin de l'Hortet A, Gilgenkrantz H. [Emergence of 3D human fatty liver models engineered in the laboratory]. Med Sci (Paris) 2020;36:261-3. [PMID: 32228845 DOI: 10.1051/medsci/2020027] [Reference Citation Analysis]
35 Liu CH, Ampuero J, Gil-Gómez A, Montero-Vallejo R, Rojas Á, Muñoz-Hernández R, Gallego-Durán R, Romero-Gómez M. miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Hepatol 2018;69:1335-48. [PMID: 30142428 DOI: 10.1016/j.jhep.2018.08.008] [Cited by in Crossref: 44] [Cited by in F6Publishing: 49] [Article Influence: 14.7] [Reference Citation Analysis]
36 Gurevich I, Burton SA, Munn C, Ohshima M, Goedland ME, Czysz K, Rajesh D. iPSC-derived hepatocytes generated from NASH donors provide a valuable platform for disease modeling and drug discovery. Biol Open 2020;9:bio055087. [PMID: 33268331 DOI: 10.1242/bio.055087] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Hsu CC, Kowdley KV. The Effects of Alcohol on Other Chronic Liver Diseases. Clin Liver Dis. 2016;20:581-594. [PMID: 27373618 DOI: 10.1016/j.cld.2016.02.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
38 Castellanos-Tapia L, Tejero-Barrera ME, Salas-Silva S, Simoni-Nieves A, Escobedo-Calvario A, Gomez-Quiroz LE. Mediterranean-like mix of fatty acids induces cellular protection on lipid-overloaded hepatocytes from western diet fed mice. Ann Hepatol 2020;19:489-96. [PMID: 32663612 DOI: 10.1016/j.aohep.2020.06.005] [Reference Citation Analysis]
39 Hasturk B, Yilmaz Y, Eren F. Potential clinical variants detected in mitochondrial DNA D-loop hypervariable region I of patients with non-alcoholic steatohepatitis. Hormones (Athens) 2019;18:463-75. [PMID: 31656024 DOI: 10.1007/s42000-019-00137-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Gholami A, Zamani F, Hosseini B, Sharafkhani R, Maadi M, Moosavi Jahromi Z, Khazaee-Pool M, Sohrabi M. Metabolic Syndrome Is Associated with Health-Related Quality of Life in Suspected Patients with Nonalcoholic Steatohepatitis. Med Princ Pract 2018;27:166-72. [PMID: 29402822 DOI: 10.1159/000487397] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
41 Wood GC, Chu X, Argyropoulos G, Benotti P, Rolston D, Mirshahi T, Petrick A, Gabrielson J, Carey DJ, DiStefano JK, Still CD, Gerhard GS. A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains. Sci Rep 2017;7:43238. [PMID: 28266614 DOI: 10.1038/srep43238] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
42 Rioux JA, Hewlett M, Davis C, Bowen CV, Brewer K, Clarke SE, Beyea SD. Mapping of fatty acid composition with free-breathing MR spectroscopic imaging and compressed sensing. NMR Biomed 2021;34:e4241. [PMID: 31898379 DOI: 10.1002/nbm.4241] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Davidson MA, Mattison DR, Azoulay L, Krewski D. Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future. Crit Rev Toxicol. 2018;48:52-108. [PMID: 28816105 DOI: 10.1080/10408444.2017.1351420] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
44 Johansen P, Howard D, Bishop R, Moreno SI, Buchholtz K. Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements. Pharmacoeconomics 2020;38:485-97. [PMID: 31919793 DOI: 10.1007/s40273-019-00881-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
45 Huang P, Huang FZ, Liu HZ, Zhang TY, Yang MS, Sun CZ. LncRNA MEG3 functions as a ceRNA in regulating hepatic lipogenesis by competitively binding to miR-21 with LRP6. Metabolism 2019;94:1-8. [PMID: 30711569 DOI: 10.1016/j.metabol.2019.01.018] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 16.5] [Reference Citation Analysis]
46 Hsu WF, Sheen LY, Lin HJ, Chang HH. A Review of Western and Traditional Chinese Medical Approaches to Managing Nonalcoholic Fatty Liver Disease. Evid Based Complement Alternat Med 2016;2016:6491420. [PMID: 27872651 DOI: 10.1155/2016/6491420] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
47 Chen X, Tan QQ, Tan XR, Li SJ, Zhang XX. Circ_0057558 promotes nonalcoholic fatty liver disease by regulating ROCK1/AMPK signaling through targeting miR-206. Cell Death Dis 2021;12:809. [PMID: 34446693 DOI: 10.1038/s41419-021-04090-z] [Reference Citation Analysis]
48 Neff EP. Farewell, FATZO: a NASH mouse update. Lab Anim (NY) 2019;48:151. [PMID: 31061508 DOI: 10.1038/s41684-019-0311-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
49 Younossi ZM, Noureddin M, Bernstein D, Kwo P, Russo M, Shiffman ML, Younes Z, Abdelmalek M. Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. Am J Gastroenterol 2021;116:254-62. [PMID: 33284184 DOI: 10.14309/ajg.0000000000001054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
50 Hanson A, Wilhelmsen D, DiStefano JK. The Role of Long Non-Coding RNAs (lncRNAs) in the Development and Progression of Fibrosis Associated with Nonalcoholic Fatty Liver Disease (NAFLD). Noncoding RNA 2018;4:E18. [PMID: 30134610 DOI: 10.3390/ncrna4030018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
51 Jiang W, Huang S, Teng H, Wang P, Wu M, Zhou X, Ran H. Diagnostic accuracy of point shear wave elastography and transient elastography for staging hepatic fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis. BMJ Open 2018;8:e021787. [PMID: 30139901 DOI: 10.1136/bmjopen-2018-021787] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 12.7] [Reference Citation Analysis]
52 Long JK, Dai W, Zheng YW, Zhao SP. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease. Mol Med 2019;25:26. [PMID: 31195981 DOI: 10.1186/s10020-019-0085-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 12.5] [Reference Citation Analysis]
53 Koeckerling D, Tomlinson JW, Cobbold JF. Fighting liver fat. Endocr Connect 2020;9:R173-86. [PMID: 32621584 DOI: 10.1530/EC-20-0174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
54 Wessels DH, Rosenberg Z. Awareness of non-alcoholic steatohepatitis and treatment guidelines: What are physicians telling us? World J Hepatol 2021; 13(2): 233-241 [PMID: 33708352 DOI: 10.4254/wjh.v13.i2.233] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
55 Kuraji R, Sekino S, Kapila Y, Numabe Y. Periodontal disease-related nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: An emerging concept of oral-liver axis. Periodontol 2000 2021;87:204-40. [PMID: 34463983 DOI: 10.1111/prd.12387] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Alsaif FA, Alqahtani SH, Alsadoon AM, Alswat KA, Abdo AA, Hassanain MM, Alsharabi AB, Aljuhani GR, Alkhalidi HM, Elsharkawy MS, Alotaibi MA, Sanai FM, Al-Hamoudi WK. Prevalence of biopsy-proven nonalcoholic fatty liver among patients with gallstone disease. Saudi J Gastroenterol. 2020;. [PMID: 32341228 DOI: 10.4103/sjg.sjg_29_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 DiStefano JK. NAFLD and NASH in Postmenopausal Women: Implications for Diagnosis and Treatment. Endocrinology 2020;161:bqaa134. [PMID: 32776116 DOI: 10.1210/endocr/bqaa134] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 14.0] [Reference Citation Analysis]
58 Grąt K, Grąt M, Rowiński O. Usefulness of Different Imaging Modalities in Evaluation of Patients with Non-Alcoholic Fatty Liver Disease. Biomedicines 2020;8:E298. [PMID: 32839409 DOI: 10.3390/biomedicines8090298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
59 Bashyam A, Frangieh CJ, Raigani S, Sogo J, Bronson RT, Uygun K, Yeh H, Ausiello DA, Cima MJ. A portable single-sided magnetic-resonance sensor for the grading of liver steatosis and fibrosis. Nat Biomed Eng 2021;5:240-51. [PMID: 33257853 DOI: 10.1038/s41551-020-00638-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Ye P, Xiang M, Liao H, Liu J, Luo H, Wang Y, Huang L, Chen M, Xia J. Dual-Specificity Phosphatase 9 Protects Against Nonalcoholic Fatty Liver Disease in Mice Through ASK1 Suppression. Hepatology 2019;69:76-93. [PMID: 30063256 DOI: 10.1002/hep.30198] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
61 Green CJ, Parry SA, Gunn PJ, Ceresa CDL, Rosqvist F, Piché ME, Hodson L. Studying non-alcoholic fatty liver disease: the ins and outs of in vivo, ex vivo and in vitro human models. Horm Mol Biol Clin Investig 2018;41:/j/hmbci. [PMID: 30098284 DOI: 10.1515/hmbci-2018-0038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
62 Nishi H, Yamanaka D, Masuda M, Goda Y, Ito K, Hakuno F, Takahashi SI. Alteration of serum amino acid profiles by dietary adenine supplementation inhibits fatty liver development in rats. Sci Rep 2020;10:22110. [PMID: 33335253 DOI: 10.1038/s41598-020-79234-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Collin de l'Hortet A, Takeishi K, Guzman-Lepe J, Morita K, Achreja A, Popovic B, Wang Y, Handa K, Mittal A, Meurs N, Zhu Z, Weinberg F, Salomon M, Fox IJ, Deng CX, Nagrath D, Soto-Gutierrez A. Generation of Human Fatty Livers Using Custom-Engineered Induced Pluripotent Stem Cells with Modifiable SIRT1 Metabolism. Cell Metab 2019;30:385-401.e9. [PMID: 31390551 DOI: 10.1016/j.cmet.2019.06.017] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 27.0] [Reference Citation Analysis]
64 Alam S, Jahid Hasan M, Khan MAS, Alam M, Hasan N. Effect of Weight Reduction on Histological Activity and Fibrosis of Lean Nonalcoholic Steatohepatitis Patient. J Transl Int Med 2019;7:106-14. [PMID: 31637181 DOI: 10.2478/jtim-2019-0023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
65 Cheah MC, McCullough AJ, Goh GB. Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease. J Clin Transl Hepatol. 2017;5:261-271. [PMID: 28936407 DOI: 10.14218/jcth.2017.00009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
66 Traber MG, Mah E, Leonard SW, Bobe G, Bruno RS. Metabolic syndrome increases dietary α-tocopherol requirements as assessed using urinary and plasma vitamin E catabolites: a double-blind, crossover clinical trial. Am J Clin Nutr 2017;105:571-9. [PMID: 28077381 DOI: 10.3945/ajcn.116.138495] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
67 Aldámiz-echevarría L, de las Heras J, Couce ML, Alcalde C, Vitoria I, Bueno M, Blasco-alonso J, Concepción García M, Ruiz M, Suárez R, Andrade F, Villate O. Non-alcoholic fatty liver in hereditary fructose intolerance. Clinical Nutrition 2020;39:455-9. [DOI: 10.1016/j.clnu.2019.02.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
68 Ghadieh HE, Muturi HT, Najjar SM. Exenatide Prevents Diet-induced Hepatocellular Injury in A CEACAM1-Dependent Mechanism. J Diabetes Treat 2017;2017. [PMID: 29431170 DOI: 10.29011/2574.7568.000033] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
69 Borges KA, Dai J, Parikh ND, Schwartz M, Nguyen MH, Roberts LR, Befeler AS, Srivastava S, Rinaudo JA, Feng Z, Marrero JA, Reddy KR. Rationale and design of the Hepatocellular carcinoma Early Detection Strategy study: A multi-center longitudinal initiative of the National Cancer Institute's Early Detection Research Network. Contemp Clin Trials 2019;76:49-54. [PMID: 30439517 DOI: 10.1016/j.cct.2018.11.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
70 Noureddin M, Anstee QM, Loomba R. Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2016;43:1109-23. [PMID: 27061197 DOI: 10.1111/apt.13620] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
71 Xu F, Guo M, Huang W, Feng L, Zhu J, Luo K, Gao J, Zheng B, Kong LD, Pang T, Wu X, Xu Q. Annexin A5 regulates hepatic macrophage polarization via directly targeting PKM2 and ameliorates NASH. Redox Biol 2020;36:101634. [PMID: 32863213 DOI: 10.1016/j.redox.2020.101634] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
72 Burton JR Jr, Helmke S, Lauriski S, Kittelson J, Everson GT. The within-individual reproducibility of the disease severity index from the HepQuant SHUNT test of liver function and physiology. Transl Res 2021;233:5-15. [PMID: 33400995 DOI: 10.1016/j.trsl.2020.12.010] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Salarian M, Turaga RC, Xue S, Nezafati M, Hekmatyar K, Qiao J, Zhang Y, Tan S, Ibhagui OY, Hai Y, Li J, Mukkavilli R, Sharma M, Mittal P, Min X, Keilholz S, Yu L, Qin G, Farris AB, Liu ZR, Yang JJ. Early detection and staging of chronic liver diseases with a protein MRI contrast agent. Nat Commun 2019;10:4777. [PMID: 31664017 DOI: 10.1038/s41467-019-11984-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
74 Attia D, Bantel H, Lenzen H, Manns MP, Gebel MJ, Potthoff A. Liver stiffness measurement using acoustic radiation force impulse elastography in overweight and obese patients. Aliment Pharmacol Ther 2016;44:366-79. [PMID: 27363528 DOI: 10.1111/apt.13710] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
75 Xu L, Zhou J, Che J, Wang H, Yang W, Zhou W, Zhao H. Mitochondrial DNA enables AIM2 inflammasome activation and hepatocyte pyroptosis in nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol 2021;320:G1034-44. [PMID: 33728991 DOI: 10.1152/ajpgi.00431.2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
76 Jayakumar S, Harrison SA, Loomba R. Noninvasive Markers of Fibrosis and Inflammation in Nonalcoholic Fatty Liver Disease. Curr Hepatol Rep 2016;15:86-95. [PMID: 27795938 DOI: 10.1007/s11901-016-0296-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
77 Ghadieh HE, Muturi HT, Russo L, Marino CC, Ghanem SS, Khuder SS, Hanna JC, Jash S, Puri V, Heinrich G, Gatto-Weis C, Lee KY, Najjar SM. Exenatide induces carcinoembryonic antigen-related cell adhesion molecule 1 expression to prevent hepatic steatosis. Hepatol Commun 2018;2:35-47. [PMID: 29404511 DOI: 10.1002/hep4.1117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
78 Zhou D, Pan Q, Liu XL, Yang RX, Chen YW, Liu C, Fan JG. Clostridium butyricum B1 alleviates high-fat diet-induced steatohepatitis in mice via enterohepatic immunoregulation. J Gastroenterol Hepatol. 2017;32:1640-1648. [PMID: 28109017 DOI: 10.1111/jgh.13742] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
79 Hong CW, Marsh A, Wolfson T, Paige J, Dekhordy SF, Schlein AN, Housman E, Deiranieh LH, Li CQ, Wasnik AP, Jang HJ, Dietrich CF, Piscaglia F, Casola G, O'Boyle M, Richman KM, Valasek MA, Andre M, Loomba R, Sirlin CB. Reader agreement and accuracy of ultrasound features for hepatic steatosis. Abdom Radiol (NY) 2019;44:54-64. [PMID: 29951900 DOI: 10.1007/s00261-018-1683-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
80 Gallo S, Calle RA, Terra SG, Pong A, Tarasenko L, Raji A. Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials. Diabetes Ther 2020;11:1849-60. [PMID: 32648108 DOI: 10.1007/s13300-020-00867-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
81 Gerhard GS, Davis B, Wu X, Hanson A, Wilhelmsen D, Piras IS, Still CD, Chu X, Petrick AT, DiStefano JK. Differentially expressed mRNAs and lncRNAs shared between activated human hepatic stellate cells and nash fibrosis. Biochem Biophys Rep 2020;22:100753. [PMID: 32258441 DOI: 10.1016/j.bbrep.2020.100753] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
82 Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 2021;184:2537-64. [PMID: 33989548 DOI: 10.1016/j.cell.2021.04.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
83 Parker A, Kim Y. The Effect of Low Glycemic Index and Glycemic Load Diets on Hepatic Fat Mass, Insulin Resistance, and Blood Lipid Panels in Individuals with Nonalcoholic Fatty Liver Disease. Metabolic Syndrome and Related Disorders 2019;17:389-96. [DOI: 10.1089/met.2019.0038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
84 Kaya E, Yılmaz Y. Non-alcoholic fatty liver disease: A growing public health problem in Turkey. Turk J Gastroenterol 2019;30:865-71. [PMID: 31258135 DOI: 10.5152/tjg.2019.18045] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
85 Dey P, Olmstead BD, Sasaki GY, Vodovotz Y, Yu Z, Bruno RS. Epigallocatechin gallate but not catechin prevents nonalcoholic steatohepatitis in mice similar to green tea extract while differentially affecting the gut microbiota. J Nutr Biochem 2020;84:108455. [PMID: 32688217 DOI: 10.1016/j.jnutbio.2020.108455] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
86 Wang G, Jin L, Li Y, Tang Q, Hu S, Xu H, Gill CA, Li M, Wang J. Transcriptomic analysis between Normal and high-intake feeding geese provides insight into adipose deposition and susceptibility to fatty liver in migratory birds. BMC Genomics 2019;20:372. [PMID: 31088359 DOI: 10.1186/s12864-019-5765-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
87 Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. Publisher Correction: The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol 2018;15:785. [PMID: 29785003 DOI: 10.1038/s41575-018-0031-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 6.7] [Reference Citation Analysis]
88 Ipsen DH, Tveden-Nyborg P. Extracellular Vesicles as Drivers of Non-Alcoholic Fatty Liver Disease: Small Particles with Big Impact. Biomedicines 2021;9:93. [PMID: 33477873 DOI: 10.3390/biomedicines9010093] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Wolfson B, Lo PK, Yao Y, Li L, Wang H, Zhou Q. Impact of miR-140 Deficiency on Non-Alcoholic Fatty Liver Disease. Mol Nutr Food Res 2018;62:e1800189. [PMID: 29701903 DOI: 10.1002/mnfr.201800189] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
90 Ratziu V, Sanyal A, Harrison SA, Wong VW, Francque S, Goodman Z, Aithal GP, Kowdley KV, Seyedkazemi S, Fischer L, Loomba R, Abdelmalek MF, Tacke F. Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. Hepatology. 2020. [PMID: 31943293 DOI: 10.1002/hep.31108] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 65.0] [Reference Citation Analysis]
91 Alexopoulou A, Pouriki S, Vasilieva L, Alexopoulos T, Filaditaki V, Gioka M, Diamantea F, Dourakis SP. Evaluation of noninvasive markers for the diagnosis of cystic fibrosis liver disease. Scand J Gastroenterol 2018;53:1547-52. [PMID: 30600723 DOI: 10.1080/00365521.2018.1534986] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
92 Barbois S, Arvieux C, Leroy V, Reche F, Stürm N, Borel A. Benefit–risk of intraoperative liver biopsy during bariatric surgery: review and perspectives. Surgery for Obesity and Related Diseases 2017;13:1780-6. [DOI: 10.1016/j.soard.2017.07.032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
93 Garvin JH, Ducom J, Matheny M, Miller A, Westerman D, Reale C, Slagle J, Kelly N, Beebe R, Koola J, Groessl EJ, Patterson ES, Weinger M, Perkins AM, Ho SB. Descriptive Usability Study of CirrODS: Clinical Decision and Workflow Support Tool for Management of Patients With Cirrhosis. JMIR Med Inform 2019;7:e13627. [PMID: 31271153 DOI: 10.2196/13627] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
94 Arista Romeu EJ, Rivera Fernández JD, Roa Tort K, Valor A, Escobedo G, Fabila Bustos DA, Stolik S, de la Rosa JM, Guzmán C. Combined methods of optical spectroscopy and artificial intelligence in the assessment of experimentally induced non-alcoholic fatty liver. Comput Methods Programs Biomed 2021;198:105777. [PMID: 33069975 DOI: 10.1016/j.cmpb.2020.105777] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Pilling D, Karhadkar TR, Gomer RH. A CD209 ligand and a sialidase inhibitor differentially modulate adipose tissue and liver macrophage populations and steatosis in mice on the Methionine and Choline-Deficient (MCD) diet. PLoS One 2020;15:e0244762. [PMID: 33378413 DOI: 10.1371/journal.pone.0244762] [Reference Citation Analysis]
96 Robison LS, Gannon OJ, Thomas MA, Salinero AE, Abi-Ghanem C, Poitelon Y, Belin S, Zuloaga KL. Role of sex and high-fat diet in metabolic and hypothalamic disturbances in the 3xTg-AD mouse model of Alzheimer's disease. J Neuroinflammation 2020;17:285. [PMID: 32993686 DOI: 10.1186/s12974-020-01956-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
97 Homayounieh F, Saini S, Mostafavi L, Doda Khera R, Sühling M, Schmidt B, Singh R, Flohr T, Kalra MK. Accuracy of radiomics for differentiating diffuse liver diseases on non-contrast CT. Int J CARS 2020;15:1727-36. [DOI: 10.1007/s11548-020-02212-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
98 Chaurasia B, Summers SA. Ceramides in Metabolism: Key Lipotoxic Players. Annu Rev Physiol 2021;83:303-30. [PMID: 33158378 DOI: 10.1146/annurev-physiol-031620-093815] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
99 Todoric J, Di Caro G, Reibe S, Henstridge DC, Green CR, Vrbanac A, Ceteci F, Conche C, McNulty R, Shalapour S, Taniguchi K, Meikle PJ, Watrous JD, Moranchel R, Najhawan M, Jain M, Liu X, Kisseleva T, Diaz-Meco MT, Moscat J, Knight R, Greten FR, Lau LF, Metallo CM, Febbraio MA, Karin M. Fructose stimulated de novo lipogenesis is promoted by inflammation. Nat Metab 2020;2:1034-45. [PMID: 32839596 DOI: 10.1038/s42255-020-0261-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 34.0] [Reference Citation Analysis]
100 Wang YL, Zhou X, Li DL, Ye JM. Role of the mTOR-autophagy-ER stress pathway in high fructose-induced metabolic-associated fatty liver disease. Acta Pharmacol Sin 2021. [PMID: 33731774 DOI: 10.1038/s41401-021-00629-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
101 Régnier M, Polizzi A, Guillou H, Loiseau N. Sphingolipid metabolism in non-alcoholic fatty liver diseases. Biochimie 2019;159:9-22. [PMID: 30071259 DOI: 10.1016/j.biochi.2018.07.021] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
102 Mukherjee S, Haubner J, Chakraborty A. Targeting the Inositol Pyrophosphate Biosynthetic Enzymes in Metabolic Diseases. Molecules 2020;25:E1403. [PMID: 32204420 DOI: 10.3390/molecules25061403] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
103 Deol P, Fahrmann J, Yang J, Evans JR, Rizo A, Grapov D, Salemi M, Wanichthanarak K, Fiehn O, Phinney B, Hammock BD, Sladek FM. Omega-6 and omega-3 oxylipins are implicated in soybean oil-induced obesity in mice. Sci Rep 2017;7:12488. [PMID: 28970503 DOI: 10.1038/s41598-017-12624-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
104 Belopolsky Y, Khan MQ, Sonnenberg A, Davidson DJ, Fimmel CJ. Ketogenic, Hypocaloric Diet Improves Nonalcoholic Steatohepatitis. J Transl Int Med 2020;8:26-31. [PMID: 32435609 DOI: 10.2478/jtim-2020-0005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
105 Zhu JZ, Hollis-Hansen K, Wan XY, Fei SJ, Pang XL, Meng FD, Yu CH, Li YM. Clinical guidelines of non-alcoholic fatty liver disease: A systematic review. World J Gastroenterol 2016; 22(36): 8226-8233 [PMID: 27688665 DOI: 10.3748/wjg.v22.i36.8226] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
106 Nobili V, Alisi A, Newton KP, Schwimmer JB. Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2016;150:1798-1810. [PMID: 27003600 DOI: 10.1053/j.gastro.2016.03.009] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 13.8] [Reference Citation Analysis]
107 Li Y, Cao C, Zhou Y, Nie Y, Cao J, Zhou Y. The roles and interaction of FXR and PPARs in the pathogenesis of nonalcoholic fatty liver disease. Arab Journal of Gastroenterology 2020;21:162-8. [DOI: 10.1016/j.ajg.2020.04.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
108 Tokuhara D. Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents. Front Nutr 2021;8:700058. [PMID: 34250000 DOI: 10.3389/fnut.2021.700058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Salvoza NC, Klinzing DC, Gopez-Cervantes J, Baclig MO. Association of Circulating Serum miR-34a and miR-122 with Dyslipidemia among Patients with Non-Alcoholic Fatty Liver Disease. PLoS One. 2016;11:e0153497. [PMID: 27077736 DOI: 10.1371/journal.pone.0153497] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 13.0] [Reference Citation Analysis]
110 El-Sebaey AM, Abramov PN. Hepatocyte-derived canine familiaris-microRNAs as serum biomarkers of hepatic steatosis or fibrosis as implicated in the pathogenesis of canine cholecystolithiasis. Vet Clin Pathol 2021. [PMID: 34031917 DOI: 10.1111/vcp.12942] [Reference Citation Analysis]
111 Gerges SH, Wahdan SA, Elsherbiny DA, El-Demerdash E. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. Life Sci 2021;271:119220. [PMID: 33592199 DOI: 10.1016/j.lfs.2021.119220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
112 Barbois S, Stürm N, Aron-Wisnewsky J, Clément K, Bedossa P, Genser L, Hilleret MN, Costentin C, Reche F, Arvieux C, Borel AL. Decision Tree for the Performance of Intraoperative Liver Biopsy During Bariatric Surgery. Obes Surg 2021;31:2641-8. [PMID: 33665755 DOI: 10.1007/s11695-021-05309-w] [Reference Citation Analysis]